Advertisement
Screener

AIM IMMUNOTECH INC. (AIM) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend

2.8 / 5 stars · 68/120 Roast Me

AIM IMMUNOTECH INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend

AIM IMMUNOTECH INC. (AIM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend of $0 for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend · last filed 2018-11-14

  • AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2018-03-31 was $0.00.
  • AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for the quarter ending 2017-03-31 was $0.00.
  • AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2017 was $0.00.
  • AIM IMMUNOTECH INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average expected dividend for fiscal 2016 was $0.00.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend 12 month
2018-09-30$0.00
10-Q · filed 2018-11-14
2018-06-30$0.00
10-Q · filed 2018-08-14
2018-03-31$0.00
10-Q · filed 2018-05-15
2017-12-31$0.00
10-K · filed 2018-03-30
2017-09-30$0.00
10-Q · filed 2017-11-14
2017-06-30$0.00
10-Q · filed 2017-08-14
2017-03-31$0.00
10-Q · filed 2017-05-15
2016-12-31$0.00
10-K · filed 2017-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
CURIS INC (CRIS)United States$0.002B-0.05
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Silexion Therapeutics Corp (SLXN)$0.001B